CN114945372A - 用肌球蛋白调节剂的治疗方法 - Google Patents

用肌球蛋白调节剂的治疗方法 Download PDF

Info

Publication number
CN114945372A
CN114945372A CN202080092267.1A CN202080092267A CN114945372A CN 114945372 A CN114945372 A CN 114945372A CN 202080092267 A CN202080092267 A CN 202080092267A CN 114945372 A CN114945372 A CN 114945372A
Authority
CN
China
Prior art keywords
subject
dose
mavacacetate
probnp
cardiac troponin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080092267.1A
Other languages
English (en)
Chinese (zh)
Inventor
T·卡尔森
C·L·德尔里奥
J·M·埃德尔伯格
S·费尔南德斯
M·P·亨策
G·Y·马
R·麦克道威尔
M·E·米利夫
A·舒耐特
M·J·赛米格兰
K·L·兰普尔
D·张
M·Y·德赛
S·尼森
方亮
J·兰宾
李婉莹
D·L·奥贝尔
B·E·凯恩
L·C·塞尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myokardia Inc
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of CN114945372A publication Critical patent/CN114945372A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202080092267.1A 2019-11-10 2020-11-10 用肌球蛋白调节剂的治疗方法 Pending CN114945372A (zh)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US201962933517P 2019-11-10 2019-11-10
US62/933,517 2019-11-10
US201962933970P 2019-11-11 2019-11-11
US62/933,970 2019-11-11
US201962935922P 2019-11-15 2019-11-15
US62/935,922 2019-11-15
US202063001473P 2020-03-29 2020-03-29
US63/001,473 2020-03-29
US202063002302P 2020-03-30 2020-03-30
US63/002,302 2020-03-30
US202063006701P 2020-04-07 2020-04-07
US63/006,701 2020-04-07
US202063022573P 2020-05-10 2020-05-10
US63/022,573 2020-05-10
US202063059143P 2020-07-30 2020-07-30
US63/059,143 2020-07-30
US202063064450P 2020-08-12 2020-08-12
US63/064,450 2020-08-12
PCT/US2020/059893 WO2021092598A1 (en) 2019-11-10 2020-11-10 Methods of treatment with myosin modulator

Publications (1)

Publication Number Publication Date
CN114945372A true CN114945372A (zh) 2022-08-26

Family

ID=75849342

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080092267.1A Pending CN114945372A (zh) 2019-11-10 2020-11-10 用肌球蛋白调节剂的治疗方法

Country Status (13)

Country Link
US (2) US20230158027A1 (cg-RX-API-DMAC7.html)
EP (1) EP4054588A4 (cg-RX-API-DMAC7.html)
JP (2) JP7830321B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220113387A (cg-RX-API-DMAC7.html)
CN (1) CN114945372A (cg-RX-API-DMAC7.html)
AU (1) AU2020378197A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022008641A2 (cg-RX-API-DMAC7.html)
CA (1) CA3157629A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022001217A1 (cg-RX-API-DMAC7.html)
IL (2) IL292840B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022005465A (cg-RX-API-DMAC7.html)
TW (1) TW202134259A (cg-RX-API-DMAC7.html)
WO (1) WO2021092598A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112939876A (zh) * 2021-03-10 2021-06-11 杭州科巢生物科技有限公司 Mavacamten的晶型I及其制备方法
CN115461052A (zh) * 2020-11-25 2022-12-09 深圳信立泰药业股份有限公司 Arb代谢产物与nep抑制剂的复合物预防和/或治疗肾病的药物用途
CN116490185A (zh) * 2020-08-28 2023-07-25 迈奥卡迪亚公司 用肌球蛋白调节剂治疗的方法

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020526483A (ja) 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
IL294501A (en) * 2020-01-28 2022-09-01 Teva Pharmaceuticals Int Gmbh Crystalline forms of Mawakamatan and procedures for obtaining them
IL302850A (en) 2020-11-12 2023-07-01 Amgen Inc Methods of treating heart failure by administering OMECAMTIV MECARBIL
KR20240015622A (ko) 2021-03-04 2024-02-05 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
WO2022189599A1 (en) * 2021-03-12 2022-09-15 Sandoz Ag Crystalline forms of mavacamten for the treatment of hcm
EP4370116B1 (en) * 2021-07-16 2025-01-15 Cytokinetics, Inc. Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
WO2023102452A1 (en) * 2021-12-02 2023-06-08 Tenax Therapeutics, Inc. Use of a combination of levosimendan and an sglt-2 inhibitor to treat heart failure
CN116410143A (zh) * 2021-12-29 2023-07-11 杭州奥默医药股份有限公司 一种多取代脲嘧啶衍生物及其制备方法和应用
WO2023133163A1 (en) * 2022-01-05 2023-07-13 Prolaio, Inc. System and method for monitoring an efficacy of a treatment for a cardiac condition
EP4508035A1 (en) 2022-04-13 2025-02-19 Assia Chemical Industries Ltd. Solid state forms of mavacamten and process for preparation thereof
CN119789856A (zh) * 2022-04-26 2025-04-08 迈奥卡迪亚公司 施用肌球蛋白抑制剂的方法
JP2024009734A (ja) * 2022-07-11 2024-01-23 国立大学法人福井大学 血圧輸液制御補助プログラム、血圧輸液制御補助装置、血圧輸液制御補助システム及び課金方法
US20240091203A1 (en) * 2022-07-20 2024-03-21 Cytokinetics, Incorporated Methods for treating non-obstructive hypertrophic cardiomyopathy
CA3268270A1 (en) 2022-09-26 2024-04-04 Edgewise Therapeutics, Inc. 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND ASSOCIATED USES
WO2024097284A1 (en) * 2022-11-02 2024-05-10 MyoKardia, Inc. Mavacamten and derivatives thereof for use in treating atrial dysfunction
JP7858148B1 (ja) 2023-03-27 2026-05-13 エッジワイズ セラピューティクス, インコーポレイテッド キナゾリンジオン化合物およびその使用
KR20250174911A (ko) 2023-03-27 2025-12-15 엣지와이즈 테라퓨틱스, 인크. 퀴놀리논 아미드 화합물 및 이의 용도
IT202300016653A1 (it) 2023-08-03 2025-02-03 Olon Spa Processo per preparare mavacamten e intermedio di processo.
WO2025046606A1 (en) 2023-08-26 2025-03-06 Micro Labs Limited Granules of mavacamten for oral administration
CN122070481A (zh) * 2023-11-01 2026-05-19 百时美施贵宝公司 基于蛋白质水平用肌球蛋白抑制剂进行治疗的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481297A (zh) * 2009-05-13 2012-05-30 心脏麦塔波里卡斯有限公司 心舒宁在治疗肥厚型心肌病(hcm)中的应用
CN105473576A (zh) * 2013-06-21 2016-04-06 迈奥卡迪亚公司 针对心脏病症的嘧啶二酮化合物
WO2019028360A1 (en) * 2017-08-04 2019-02-07 MyoKardia, Inc. MAVACAMTEN FOR USE IN THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3399907A4 (en) * 2016-01-04 2019-08-28 Aventusoft, LLC SYSTEM AND METHOD FOR MEASURING HEMODYNAMIC PARAMETERS FROM THE HEADLAPPING SIGNALS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481297A (zh) * 2009-05-13 2012-05-30 心脏麦塔波里卡斯有限公司 心舒宁在治疗肥厚型心肌病(hcm)中的应用
CN105473576A (zh) * 2013-06-21 2016-04-06 迈奥卡迪亚公司 针对心脏病症的嘧啶二酮化合物
WO2019028360A1 (en) * 2017-08-04 2019-02-07 MyoKardia, Inc. MAVACAMTEN FOR USE IN THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARK P GRILLO ET AL: "In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin", 《XENOBIOTICA》, vol. 49, no. 6, 1 October 2018 (2018-10-01), pages 718 - 733 *
曹永彤等: "《医学检验大百科》", 30 June 2017, 中国医药科技出版社, pages: 484 - 485 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116490185A (zh) * 2020-08-28 2023-07-25 迈奥卡迪亚公司 用肌球蛋白调节剂治疗的方法
CN115461052A (zh) * 2020-11-25 2022-12-09 深圳信立泰药业股份有限公司 Arb代谢产物与nep抑制剂的复合物预防和/或治疗肾病的药物用途
CN115461052B (zh) * 2020-11-25 2023-12-22 深圳信立泰药业股份有限公司 Arb代谢产物与nep抑制剂的复合物预防和/或治疗肾病的药物用途
CN112939876A (zh) * 2021-03-10 2021-06-11 杭州科巢生物科技有限公司 Mavacamten的晶型I及其制备方法

Also Published As

Publication number Publication date
KR20220113387A (ko) 2022-08-12
MX2022005465A (es) 2022-08-08
CL2022001217A1 (es) 2023-01-13
US20230158027A1 (en) 2023-05-25
JP2023501453A (ja) 2023-01-18
CL2026001520A1 (es) 2026-06-19
CA3157629A1 (en) 2021-05-14
TW202134259A (zh) 2021-09-16
EP4054588A1 (en) 2022-09-14
IL292840B1 (en) 2026-07-01
AU2020378197A1 (en) 2022-05-26
JP7830321B2 (ja) 2026-03-16
US20260207600A1 (en) 2026-07-23
JP2026094345A (ja) 2026-06-09
EP4054588A4 (en) 2023-12-13
BR112022008641A2 (pt) 2022-09-13
WO2021092598A1 (en) 2021-05-14
IL292840A (en) 2022-07-01
IL328632A (en) 2026-07-01

Similar Documents

Publication Publication Date Title
JP7830321B2 (ja) ミオシンモジュレーターによる治療方法
US12616697B2 (en) Methods of treatment with myosin modulator
US20250241903A1 (en) Treatment of systolic dysfunction
AU2018311974A1 (en) Mavacamten for use in the treatment of hypertrophic cardiomyopathy
JP7832128B2 (ja) 心房機能不全の治療
HK40077232A (en) Methods of treatment with myosin modulator
EA052373B1 (ru) Способы лечения модулятором миозина
US20250325531A1 (en) Treatment of systolic dysfunction
HK40061292A (en) Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide
HK40091633A (en) Treatment of atrial dysfunction
Friedrich et al. Telmisartan Effectiveness on Left ventricular MAss Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension—a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months—rationale and study design

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40077232

Country of ref document: HK